Medical Approaches in Adrenocortical Carcinoma

Medical Approaches in Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) represents one of the most aggressive endocrine tumors. In spite of a correct therapeutic strategy based on a multidisciplinary approach between endocrinologist, surgeon and oncologist, the prognosis is often poor. Surgery is the mainstay treatment in ACC. Mitotane, a...

Full description

Bibliographic Details
Main Authors:	Rosa Maria Paragliola, Andrea Corsello, Pietro Locantore, Giampaolo Papi, Alfredo Pontecorvi, Salvatore Maria Corsello
Format:	Article
Language:	English
Published:	MDPI AG 2020-11-01
Series:	Biomedicines
Subjects:	adrenocortical carcinoma mitotane etoposide cisplatin doxorubicin immune checkpoint inhibitors
Online Access:	https://www.mdpi.com/2227-9059/8/12/551

Similar Items

Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease
by: Rossella Libé, et al.
Published: (2023-01-01)

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
by: Nadia Gagnon, et al.
Published: (2023-01-01)

Clinical results of the use of mitotane for adrenocortical carcinoma
by: A.A. Kasperlik-Zaluska
Published: (2000-10-01)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
by: Jonathan Poirier, et al.
Published: (2020-03-01)

A case of adrenocortical carcinoma accompanying secondary acute adrenal hypofunction postoperation
by: Kai Kou, et al.
Published: (2018-03-01)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
by: Marta Laganà, et al.
Published: (2020-04-01)

Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma
by: You Joung Heo, et al.
Published: (2022-09-01)

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
by: Marco Lo Iacono, et al.
Published: (2021-10-01)

Adrenocortical Carcinoma With Cushing’s Syndrome and Hyperandrogenism in a 28-Year-Old Pregnant Female
by: Michael John Marino, DO, et al.
Published: (2023-05-01)

Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions
by: Sara Bedrose, et al.
Published: (2020-02-01)

Adrenocortical cancer: late diagnosis of the disease on the example of a clinical case. Case report
by: Evgenia A. Starostina, et al.
Published: (2023-12-01)

Adrenocortical carcinoma: A tumor with poor answer to classic chemotherapy
by: Sava Alexandra Daniela, et al.
Published: (2023-12-01)

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options
by: Ruaa Al-Ward, et al.
Published: (2023-01-01)

Massive adrenocortical carcinoma presenting as peripheral edema: a case report
by: David A. Goodkin
Published: (2022-06-01)

Health-Related Quality of Life in Adrenocortical Carcinoma
by: Rebecca V. Steenaard, et al.
Published: (2019-10-01)

Adrenocortical carcinoma (ACC): diagnosis, prognosis and treatment.
by: Rossella eLibé
Published: (2015-07-01)

Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?
by: Yoann Cazaubon, et al.
Published: (2019-10-01)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
by: Antonina Germano, et al.
Published: (2020-04-01)

The experience with the application of first-line chemotherapy regimen with EDP-M (etoposide + doxorubicin + cisplatin + mitotane) in patients with advanced adrenocortical carcinoma in the Russian Federation
by: A A Kolomeytseva, et al.
Published: (2017-09-01)

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
by: Masaya Senda, et al.
Published: (2023-11-01)

Isosexual precocious pseudopuberty during mitotane treatment in a child with adrenocortical carcinoma: A case report
by: Maria Riedmeier, et al.
Published: (2024-06-01)

The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells
by: Elaine Silveira, et al.
Published: (2018-03-01)

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study
by: Marilda Mormando, et al.
Published: (2023-08-01)

Hypogonadism and sexual function in men affected by adrenocortical carcinoma under mitotane therapy
by: Letizia Canu, et al.
Published: (2024-01-01)

Prominent 18F-FDG Uptake in the Adrenal Gland after Contralateral Adrenalectomy in a Known Case of Adrenocortical Oncocytic Carcinoma
by: Rakan Al-Rashdan, et al.
Published: (2023-06-01)

Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience
by: Li-Hsin Pan, et al.
Published: (2023-03-01)

Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma
by: Rosa Maria Paragliola, et al.
Published: (2023-01-01)

Long-term partial response in a patient with liver metastasis of primary adrenocortical carcinoma with adjuvant mitotane plus transcatheter arterial chemoembolization and microwave ablation: a case report
by: Jianhua Deng, et al.
Published: (2023-05-01)

Exploring the role of systemic therapy in adult adrenocortical carcinoma: A single-center experience
by: Akhil Kapoor, et al.
Published: (2020-01-01)

Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry
by: Rebecca V. Steenaard, et al.
Published: (2022-03-01)

The impact of mitotane therapy on serum-free proteins in patients with adrenocortical carcinoma
by: Magdalena Lech, et al.
Published: (2024-02-01)

Local advanced adrenocortical cancer with a long‐term recurrence‐free survival treated with complete surgical excision and adjuvant therapy with a very low‐dose mitotane
by: Yuumi Tokura, et al.
Published: (2020-11-01)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
by: Vittoria Basile, et al.
Published: (2021-04-01)

Re-Evaluation of Combinational Efficacy and Synergy of the Italian Protocol In Vitro: Are We Truly Optimizing Benefit or Permitting Unwanted Toxicity?
by: Chitra Subramanian, et al.
Published: (2021-09-01)

The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma
by: Izabela Karwacka, et al.
Published: (2021-01-01)

Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids
by: Carolin Langer, et al.
Published: (2022-09-01)

CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis
by: Liwen Ren, et al.
Published: (2022-10-01)

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
by: Elisa Rossini, et al.
Published: (2021-06-01)

Complete Remission of Advanced Adrenocortical Cancer Following Mitotane Monotherapy: A Case Report and Literature Review of Predictive Markers
by: Judit Tőke, et al.
Published: (2021-05-01)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
by: Obada Ababneh, et al.
Published: (2024-02-01)